| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $38.6M | -6.4% |
| Cost of Revenue | $7.1M | +49.7% |
| Gross Profit | $31.5M | -13.7% |
| R&D Expense | $22.2M | -6.7% |
| SG&A Expense | $29.7M | -1.2% |
| Operating Income | -$51.2M | -6.0% |
| Pre-tax Income | -$41.1M | -8.3% |
| Net Income | -$41.1M | -8.3% |
| EPS (Basic) | -$0.39 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $27.9M | -40.0% |
| Short-term Investments | $126.6M | +4.0% |
| Accounts Receivable | $4.7M | -19.0% |
| Inventory | $8.9M | -27.1% |
| Current Assets | $171.7M | -9.7% |
| Total Assets | $239.5M | -10.7% |
| Current Liabilities | $15.8M | -11.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$27.6M | -27.3% |
| Capital Expenditures | $1.7M | -55.4% |
| Investing Cash Flow | $6.9M | -87.4% |
| Financing Cash Flow | $2.1M | -4.1% |
| Free Cash Flow | -$29.3M | -15.3% |
| -5.4% |
| EPS (Diluted) | -$0.39 | -5.4% |
| Total Liabilities |
| $33.2M |
| -8.0% |
| Stockholders' Equity | $206.3M | -11.2% |